1. At a Glance – The “Doctor, Patient is Alive But ICU Bill Is Huge” Moment
There are companies that make money.
There are companies that burn money.
And then there are companies like Sastasundar Ventures — which somehow manage to lose money operationally, but still show profits thanks to “other income” like a magician pulling rabbits out of treasury investments.
Welcome to India’s most confusing healthcare platform story.
On one hand, you’ve got a company doing ₹1,231 Cr revenue annually, building a pharma supply chain network touching 65,000 retailers, partnering with Flipkart, launching private labels, AI SaaS tools, and dreaming of becoming “Health X Platform Ltd.”
On the other hand, operating profit is negative, margins are thinner than a roadside dosa, and profitability seems to depend heavily on treasury income and accounting gymnastics.
And just when you think things can’t get more dramatic, they throw in:
- A name change (because rebranding solves everything, right?)
- A complex merger + demerger structure
- A stake sale to Flipkart ecosystem
- And a new private label business (JITO) promising 30% margins
So what exactly is happening here?
Is this:
- A hidden multi-bagger platform story?
- A restructuring puzzle that only investment bankers understand?
- Or a company trying to turn a logistics business into a tech startup mid-flight?
Let’s investigate.
Because this is not a stock analysis…
This is a financial crime thriller without the crime (hopefully).
2. Introduction – From Pharmacy App to Corporate Restructuring Circus
Sastasundar started as a simple idea:
“Let’s sell medicines online.”
Somewhere along the way, management said:
“Why stop there? Let’s build a full-stack healthcare + financial services + platform + AI + private label + supply chain + NBFC hybrid monster.”
Classic Indian corporate ambition.
Today, the company operates through multiple subsidiaries:
- HealthBuddy (B2C)
- RetailerShakti (B2B)
- Genu Path Labs (Diagnostics)
- Microsec (Financial services)
And if that wasn’t enough, they are now:
- Renaming themselves to Health X Platform Ltd
- Planning a merger + demerger combo
- Splitting healthcare and NBFC businesses
It’s like:
“We tried everything… now let’s reorganize the company and hope the market understands.”
Meanwhile, Q3 FY26 numbers came in:
- Revenue: ₹341 Cr
- PAT: ₹1.13 Cr
- EBITDA: still negative
So technically profitable… but only if you ignore operations.
Now let me ask you:
👉 If your business loses money but your investments save you… are you a business or a mutual fund?
3. Business Model – WTF Do They Even Do?
Let’s simplify this mess.
1. B2B – RetailerShakti (The Real Engine)
This is the backbone:
- Supplies medicines to pharmacies
- Competes with traditional distributors
- Offers:
- Next-day delivery
- No credit (big USP)
- Slightly higher discounts
Management claims:
- Retailers reduce inventory from 40 days → 10 days
- No-credit model improves efficiency
Basically:
“We won’t give you credit… but we’ll give you better pricing so you don’t complain.”
Sounds like your local kirana store owner negotiating.
2. B2C – HealthBuddy / SastaSundar
This is the consumer-facing app.
- Orders placed digitally
- Delivered via local “HealthBuddy partners”
- No delivery cost (they claim)
Management says:
- Already contribution margin positive in Jan
- Will be fully profitable by FY28–30
Translation:
“We are not losing money per order… just losing money overall.”
3. Diagnostics – Genu Path Labs
- Pathology + radiology
- Focus on Eastern India
- Still early-stage
Not much contribution yet.
4. Financial Services
- Investments
- Lending
- Wealth management
Also known as:
👉 “The reason PAT exists.”
5. JITO – The New Hero Entry
Private-label generic medicines:
